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A B S T R A C T
Objective: This study aims to validate the prognostic signiﬁcance of the expression of Monocarboxylate
Transporter 4 (MCT4) in patients with colorectal liver metastases (CRLM). This study investigated the
correlation between MCT4 expression in stromal and tumor cells of colorectal liver metastases (CRLM)
with disease-free (DFS) and overall survival (OS) in liver-only colorectal metastases treated with liver
resection following neoadjuvant chemotherapy.
Methods: This is a retrospective study of 107 patients with colorectal liver metastases. MCT4 expres-
sion in both stromal and tumor cells was studied by immunohistochemistry. The staining was scored
semiquantitatively as weak or strong. DFS and OS were calculated using both Kaplan–Meier and multi-
variate Cox-regression methods
Results: Specimens from 57 patients (53.27%) showed weak levels of stromal MCT4 staining, whereas
50 patients (46.73%) showed strong levels of MCT4 staining. From the statistical analysis, strong stromal
MCT4 expression was associated with decreased DFS (HR 1.79; 95% CI, 1.12–2.85; P = 0.014) and OS (HR
3.81 95% CI, 1.88–7.72; P < 0.001) in univariate analysis. This ﬁnding remained signiﬁcant in multivari-
ate analysis for both DFS and OS (HR 1.95; 95% CI, 1.19–3.17; P = 0.007, and HR 4.38; 95% CI, 2.15–8.92;
P < 0.001 respectively). Tumeur MCT4 expression was not associated with DFS and OS. Five-years DFS
and OS rates were 43% and 78% respectively in patients with weak and 15% and 37% respectively in pa-
tients with strong stromal MCT4 expression.
Conclusion: Our results indicated that strong expression of stromal MCT4 in CRLM was associated with
poor prognosis in patients who undergo liver resection for liver-only colorectal metastases. This ﬁnding
could be furthermore validated in independent studies and MCT4 could be used as a new biomarker in
CRLM and creates the possibility of new studies in targeted therapies.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Globally, more than one million people are diagnosed with
colorectal cancer every year resulting in about 715,000 deaths as
of 2010 which is signiﬁcantly higher compared to 490,000 deaths
in 1990 [1]. Since 2012, it is the second most common cause of
cancer in women (9.2% of diagnoses) and the third most common
in men (10.0% of diagnoses) [2]. Its prevalence is higher in devel-
oped than developing countries. Current therapy is a combination
of surgery and chemotherapy. Recent advances in chemotherapy have
improved overall survival of patients with colorectal cancer, espe-
cially the subgroupwithmetastases, but overall survival still remains
relatively low [3]. Patients with resectable colorectal cancer liver
metastases have ﬁve-year overall survival of 35–58%. However, these
patients have high recurrence rate and only about 15%will be disease
free ten years after liver resection [4]. Identifying prognostic factors
of recurrence could help better therapy planning. In addition, re-
search for new therapies is evolving and electivemolecules that could
be targeted are a promising area of investigation [5].
To date, a number of prognostic factors such as grade (tumor dif-
ferentiation), N-status, large bowel obstruction, operation, primary
tumor resection, location, number and size of liver lesions, extra-
hepatic transfer, preoperative CEA level and chemotherapy have been
evaluated [6].
Monocarboxylate transporter 4 (MCT4), also known as solute
carrier family 16a member, is a membrane transporting protein that
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in humans are encoded by the SLC16A3gene [7]. Northern and
Western blotting and EST database analyses showed MCT4 to be
widely expressed in glycolytic tissues such as white skeletal muscle
ﬁbers, astrocytes, white blood cells, chondrocytes, and some mam-
malian cell lines. Due to this selective expression, it has been
identiﬁed that MCT4 serves lactate export from the cytoplasm, pro-
duced by glycolysis. The MCT family counts 14 members and only
MCT1-MCT4 catalyze the trans membrane proton-coupled trans-
port of lactate [8].
The “reverse Warburg” effect is a two compartment model of
cancer cells energy metabolism that was ﬁrst thorough studied in
humans as a concern to breast cancer. According to this model,
glycolytic tumor stroma (cancer-associated ﬁbroblasts, CAF’s) trans-
fers energy-rich nutrients, such as lactate, to tumor cells, which is
the ﬁrst step in initiating mitochondrial metabolism in these
cancer cells [9].
Using the “reverse Warburg” effect, we considered that MCT4
could be a new biomarker for the clinical outcome of patients with
colorectal cancer and liver metastases. MCT4 is the major mem-
brane transporter responsible for L-Lactate eﬄux-export from
glycolytic cells and as such is a biomarker of oxidative stress and
aerobic glycolysis in the tumor stroma. As proved in breast cancer,
MCT4 is overexpressed in stromal ﬁbroblasts, and this overexpression
is associated with poor overall survival [10].
We used immunochemistry to investigate the level of expres-
sion of MCT4 in the stroma that surrounds cancer cells of colorectal
liver metastases. The level of MCT4 expression was then associ-
ated with the clinicopathological features of these patients.
2. Materials and methods
2.1. Patient selection and clinical information
We derived our data from two retrospectively surgical data-
bases: 1st Department of Surgery, Laiko General Hospital, University
of Athens, Greece and Nicosia General Hospital, University Hospi-
tal, Cyprus. Patients who underwent liver resection between January
2001 and December 2012 for CRLM were identiﬁed. Eligible pa-
tients for the studywere patients without extra-hepatic disease, who
received neoadjuvant chemotherapy, had a complete tumor resec-
tion, did not deceased because of postoperative complications and
ﬁnally had adequate tissue samples for the evaluation of MCT4
expression.
Exclusion of extra-hepatic disease was performed preopera-
tively as routine with chest, abdomen and pelvis computed
tomography. Resectability was evaluated from an interdisciplin-
ary board constituted by a surgical expert, an oncologist, and a
radiologist. All resections were initiated with a curative intent.
All institutional electronic records were evaluated for each patient
and data were collected regarding: a) standard demographics, b)
primary colorectal tumor, c) CRLM characteristics, d) preoperative
chemotherapy, e) response to preoperative chemotherapy, f) liver
resection g) DFS and the OS.
2.2. Immunohistochemical staining
Immunohistochemical staining for MCT4was performed on 3 μm
thick formalin-ﬁxed paraﬃn sections, using a two-step technique
after overnight heating at 37°C and subsequent deparaﬃnization
in xylene and rehydration through graded alcohols. After the quench-
ing of the endogenous peroxidase activity, using methanol hydrogen
peroxide solution (0.3% in TBS for 30 min) we proceeded to
microwave-mediated antigen retrieval in ethylenediaminetetraacetic
acid (EDTA) at pH 9.0 for 10 min. Subsequently, sections were in-
cubated overnight at 4°C with the primary antibodies (MCT4, clone
sc-50329, Santa Cruz Biotechnology Inc., USA). A two-step tech-
nique (Quanto, Thermo – Fischer Scientiﬁc Inc., USA) was used.
Diaminobenzidine was used as a chromogen. Finally, sections were
counterstained with hematoxylin and mounted. As positive con-
trols, we used placenta (MCT4) sections previously known to be
highly immunoreactive for the studied markers. Negative controls
had the primary antibody omitted and replaced by nonimmune
normal serum from the same species as the primary antibody or
TBS.
2.3. Immunohistochemical evaluation
The evaluation of the immunohistochemical staining was per-
formed by a pathologist (G.A.) through lightmicroscopic observation,
who was unaware of the clinical data of each patient. The
immunoexpression of MCT4 bothmembranous and cytoplasmic was
localized to stromal ﬁbroblasts, tumor cells, endothelial cells of blood
vessels, adipocytes, and smooth muscle cells. MCT4, mainly mem-
branous, showed more narrow expression in stromal ﬁbroblasts,
tumor cells, and inﬂammatory cells. Immunoreactivity for MCT4was
estimated in a semiquantitative manner by the evaluation of stain-
ing intensity (score 0: no staining, score 1: weak staining, score 2:
moderate staining and score 3: strong staining) and the extent of
positive tumor cells over the total number of tumor cells (score 0:
no staining, score 1: < 25% of tumor stained, score 2:25–50% of tumor
stained, score 3: 50–75% of tumor stained, score 4: > 75% of tumor
stained). For both stromal and tumor cells, a total (staining inten-
sity plus staining extend) equal or less of 5 was categorized as weak
expression, while a total higher than 5 was categorized as the strong
expression.
2.4. Statistical analysis
Statistical analyses were performed using the Statistical Package
for Social Sciences software (SPSS), version 17.0. The primary and
secondary endpoints of the study were DFS and OS respectively. DFS
was calculated from the date of hepatectomy to the date of disease
recurrence and was censored at the last follow-up or at the time
of death if the patients remained tumor free at that time. OS was
calculated from the time of hepatectomy to the date of cancer-
related death and was censored at last follow-up or at the time of
unrelated to cancer death. Chi-square test was used for calculat-
ing the association between patients’ and tumor’s categorical
characteristics and stromal and tumor cells MCT4 expression. The
impact of these features on DFS and OS was analyzed using the
Kaplan–Meier method. Survival outcomes between groups were
compared with the log-rank test. A P value of less than 0.05 was
considered statistically signiﬁcant. Factors that were associated with
the DFS or the OS (P > 0.1) in univariate analysis were used for the
performance of the multivariate Cox-regression analysis.
3. Results
A total of 107 patients were enrolled. The demographic charac-
teristics of the patients and the characteristics of CRLM at diagnosis
are shown in Table 1. The stromal MCT4 expression was strong in
50 patients (46.7%). Immunochemistry staining is shown in Images 1
and 2. As demonstrated in Table 1, there was no statistically sig-
niﬁcant difference in patient’s and CRLM’s characteristics between
patients withweak and strong stromalMCT4 expression. Themedian
follow-up period was 39 months (2 to 102 months). During the
follow-up period, 72 patients (67.3%) developed tumor recurrence
and 38 (35.5%) patients died due to progressive disease. Within the
group of patients with strong stromal MCT4 expression of the re-
currence rate was much higher, as 40 out of 50 (80%) patients
developed tumor recurrence. The corresponding rate for the group
of patients with weak stromal MCT4 expression was 56.1% (80% vs
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56.1%, P = 0.009). The cancer-related death occurred in 27 of 50 (54%)
patients with strong stromal MCT4 expression and in 11 of 57 (19%)
patients with weak stromal MCT4 expression (P < 0.001). (Fig. 1)
Univariate analyses (Table 2) demonstrated that more than 3 liver
metastases at diagnosis (HR 2.27; 95% CI, 1.36–3.80;P = 0.002), bilobal
distribution of lesions (HR 2.41; 95% CI, 1.47–3.94;P < 0.001), disease
progression during neoadjuvant chemotherapy according to RECIST
criteria [11] (HR 3.84; 95% CI, 1.91–7.71;P < 0.001), no adjuvant-
post hepatectomy chemotherapy (HR 2.27; 95% CI, 1.34–
3.84;P = 0.002), and strong stromal MCT4 expression (HR 1.79; 95%
CI, 1.12–2.85;P = 0.014) were associatedwith a decreased DFS. Tumor
cells MCT4 expression was not associated with DFS (HR 0.70; 95%
CI, 0.43–1.12; P = 0.145). Patients with strong stromal MCT4 ex-
pression had a median DFS of 10.5 months compared to a DFS of
20.4 months for the patients with weak stromal MCT4 expression.
Three and 5-years DFS rates were 25% and 15% respectively in pa-
tients with strong stromal MCT4 expression and 43% and 35%
respectively in patients with weak stromal MCT4 expression. Re-
garding OS, univariate analysis (Table 2) revealed that bilobal
distribution of lesions (HR 2.87; 95% CI, 1.49–5.54; P = 0.002), no
adjuvant-post hepatectomy chemotherapy (HR 3.04; 95% CI, 1.54–
5.99; P = 0.001), and strong stromal MCT4 expression (HR 3.81; 95%
CI, 1.88–7.72; P < 0.001) were associated with decreased OS (Fig. 2).
Tumor cells MCT4 expression was not associated with OS (HR 1.02;
95% CI, 0.53–1.95; P = 0.946). Patients with strong stromal MCT4 ex-
pression had a median OS of 56 months, and median OS was not
reached in patients with weak stromal MCT4 expression. Three and
ﬁve years OS rates were 61% and 37% respectively in patients with
strong stromal MCT4 expression and 89% and 78% respectively in
patients with weak stromal MCT4 expression.
Multivariate analysis for DFS was adjusted for a number of CRLM:
distribution of CRLM, preoperatively administration of Bevacizumab,
response to neoadjuvant chemotherapy, administration of adjuvant-
post hepatectomy chemotherapy, and stromal MCT4 expression. For
OS the multivariate analysis was adjusted for distribution of CRLM,
administration of adjuvant-post hepatectomy chemotherapy, and
stromal MCT4 expression. In multivariate analysis factors which re-
mained statistically associated with DFS include bilobal distribution
of lesions (HR 2.05; 95% CI, 1.15–3.65; P = 0.015), progression during
pre-operative chemotherapy (HR 3.60; 95% CI, 1.62–7.99; P = 0.002),
and strong stromal MCT4 expression (HR 1.95; 95% CI, 1.19–3.17;
P = 0.007) (See Table 2). Strong stromal MCT4 expression was the
most signiﬁcant factor associated with decreased OS on MVA (HR
4.38; 95% CI, 2.15 – 8.92, P < 0.001), although bilobal distribution
of lesions (HR 2.59; 95% CI, 1.23–5.45; P = 0.012) also remained sta-
tistically associated with overall survival in this analysis (see Table 2).
Table 1
Relationships between baseline clinicopathologic characteristics and Stromal MCT4 expression.
Stromal MCT4 expression P-value
Parameter Total Weak Strong
Age at operation
≤ 65 yr 67(62.6%) 34(59.6%) 33(66%)
>65 yr 40(37.4%) 23(40.4%) 17(34%) 0.551
Gender
Female 42(39.3%) 22(38.6%) 20(40%)
Male 65(60.7%) 35(61.4%) 30(60%) 0.999
No. of metastasis at diagnosis
≤ 3 81(75.7%) 43(75.4%) 38(76%)
>3 26(24.3%) 14(24.6%) 12(24%) 0.999
Distribution of lesions
Unilobar 69(64.5%) 35(61.4%) 34(68%)
Bilobar 38(35.5%) 22(38.6%) 16(32%) 0.546
Size of largest metastases
≤ 5 cm 83(77.6%) 46(80.7%) 37(74%)
>5 cm 24(22.4%) 11(19.3%) 13(26%) 0.473
Timing of metastasis
Synchronous 75(70.1%) 39(68.4%) 36(72%)
Metachronous 32(29.9%) 18(31.6%) 14(28%) 0.833
Type of neoadjuvant chemotherapy
Oxaliplatin-based chemotherapy 68(63.6%) 39(68.4%) 29(58%)
Irinotecan- based chemotherapy 38(35.5%) 18(31.6%) 20(40%)
Unknown 1(0.9%) 0(0%) 1(2%) 0.417
Preoperative administration of bevacizumab
No 64(59.8%) 35(61.4%) 29(58%)
Yes 43(40.2%) 22(38.6%) 21(42%) 0.436
Response to neoadjuvant chemotherapya
Respondersa 97(90.7%) 53(93%) 44(88%)
Progression 10(9.3%) 4(7%) 6(12%) 0.377
No. of segments removed
≤ 3 52(48.6%) 30(52.6%) 22(44%)
>3 55(51.4%) 27(47.4%) 28(56%) 0.440
Primary tumor in situ at the time of hepatectomy
No 88(82.2%) 47(82.5%) 41(82%)
Yesb 19(17.8%) 10(17.5%) 9(18%) 0.999
Adjuvant chemotherapy
Yes 80(74.8%) 43(75.4%) 37(74%)
No 27(25.2%) 14(24.6%) 13(26%) 0.999
Tumeur MCT4 expression
Weak 55(51.4%) 29(50.9%) 26(52%)
Strong 51(47.7%) 27(47.3%) 24(48%)
Unknown 1(0.9%) 1(1.8%) 0(0%) 0.999
a Radiologic complete response or radiologic partial response or stable disease (according to RECIST).
b 15 patients underwent synchronous resection of primary tumor and CRLM and 4 patients were managed with the ‘liver ﬁrst’ approach.
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4. Discussion
It is now recognized that cancer cells display unique metabolic
pathways that inﬂuence the biological behavior of the tumor and
have prognostic and therapeutic consequences [12]. One of these
types of metabolic adaption is the use of lactate for energy supply.
A study of the literature suggests that MCT4 functions predomi-
nantly as a membrane transporter that removes lactate from a
number of cells that use aerobic glycolysis for energy metabolism
and have no functional mitochondria [13]. MCT4 is expressed at high
levels in white skeletal muscle ﬁbers, speciﬁcally in fast-twitch ﬁbers
(type 2 muscle ﬁbers) and at lower levels in other tissues, such as
testis, lung, and placenta, and in some cell types such as
chondrocytes, leukocytes, and astrocytes [14,15]. MCT4 expres-
sion is upregulated during hypoxia and is a well deﬁned HIF1 target
gene [16,17]. After lactate is pushed out by MCT4, it is further taken
by other MCT transporters in adjacent cells, such as slow-twitch
ﬁbers in muscle or neurons in the brain. To extract lactate from their
micro-environment, slow-twitch muscle ﬁbers use MCT1, while
neurons use principally MCT2. MCT1 and MCT2 are similar in their
structure and function [11]. This mechanism of nutrients ex-
change was named “neuroglia metabolic coupling” in the brain and
“lactate shuttle” in skeletal muscle [16]. The reverse Warburg effect
in human cancers cells was ﬁrst proposed by Dr. Michael P. Lisanti
and colleagues in 2009 after extensive research on breast cancer.
According to this innovative model, aerobic glycolysis actually takes
place in tumor-associated ﬁbroblasts, and not in cancer cells them-
selves. Researchers called this new observation “The ReverseWarburg
Effect” to distinguish it from the conventional Warburg Effect, which
was originally described to take place in tumor cells [8,9,18].
Tumor cells secrete hydrogen peroxide (H2 O2) to induce oxi-
dative stress (pseudohypoxia) which activates the production of
reactive oxygen species (ROS). The effects of ROS on cell metabo-
lism are well documented in a variety of studies [19]. These include
Fig. 1. Patients with strong stromal MCT4 expression had worse DFS than patients
with weak stomal MCT4 expression.
Image 1. Strong mct4 expression in cancer and in stromal cells.
Image 2. Weak mct4 expression in cancer and in stromal cells.
Fig. 2. Patients with strong stromal MCT4 expression had worse OS than patients
with weak stomal MCT4 expression.
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not only participation in apoptosis but also a number of positive
effects including the induction of host defense, mobilization of trans-
porting systems and consequently control of cellular function. As
an example, platelets involved in wound repair and blood homeo-
stasis release ROS to recruit additional platelets to sites of injury
[20,21]. ROS increased production in stromal ﬁbroblasts induces the
activation of NFκB and HIF1-α transcription factors. The ﬁnal results
of these cellular alterations are autophagy/mitophagy, inﬂamma-
tion and aerobic glycolysis. Through the samemechanism, oxidative
stress increases the production of MCT4 [18].
The ‘stimulation’ of the stroma by the tumor cells also results in
the production of nucleotides, fatty acids and amino acids, such as
glutamine. These catabolites products stimulatemitochondrial bio-
genesis, oxidative phosphorylation (OXPHOS) and resistance in
autophagy in epithelial cancer cells, protecting them against
chemotherapy-induced apoptosis [22]. This succession of events has
important consequences in tumor growth and inevitably in the clin-
ical outcome of the patient. Aerobic glycolysis in cancer adjacent
ﬁbroblasts results in theproduction of high-energymetabolites (such
as lactate and pyruvate), which can then be transferred with the
aid of MCT4 and other MCT transporters to adjacent cancer cells
undergoing oxidativemitochondrial metabolism for energy supply.
The ﬁnal outcome is the increased production of ATP in cancer cells,
driving tumor growth and metastasis. In summary, this new par-
adigm states that stromal ﬁbroblasts are feeding cancer cells via the
transfer of high-energymetaboliteswith theaidof amonocarboxylate
transporter (MCT) [23,24].
These new ﬁndings change what was believed for decades about
cancer cell metabolism. Cancer cells themselves induce “The Reverse
Warburg Effect” in their microenvironment by using oxidative stress
to promote aerobic glycolysis, under conditions of normal oxygen
supply. In our study, we investigated the compartment-speciﬁc ex-
pression of MCT4 in patients with CRLM and determined its potential
association with overall clinical outcome. We proved that in-
creased stromal MCT4 expression is associated with poor DFS and
OS. In contrast, the expression of MCT4 in tumor cells had no cor-
relation with the clinical outcome, thus had no prognostic value.
Our results are consistent with other studies which proved that
increased lactic concentration in tumor cells correlate with poor clin-
ical outcome. In addition, our results correlate with observations
Table 2
Baseline clinicopathologic characteristics and their association with DFS and OS in univariate analysis and multivariate analysis.
DFS OS
Univariate analysis Μultivariate analysis Univariate analysis Μultivariate analysis
Parameter HR(95% CI) P- value HR(95% CI) P-value HR(95% CI) P-value HR(95% CI) P-value
Age at operation
≤ 65 yr 1(referent) 1(referent) 1(referent)
>65 yr 0.89(0.52–1.46) 0.665 1.64(0.86–3.12) 0.130
Gender
Female 1(referent) 1(referent)
Male 1.50(0.91–2.47) 0.104 1.31(0.66–2.61) 0.428
No. of metastasis at diagnosis
≤ 3 1(referent) 1(referent) 1(referent)
>3 2.27(1.36–3.80) 0.002 1.67(0.94–2.96) 0.076 1.63(0.79–3.37) 0.182
Distribution of lesions
Unilobar 1(referent) 1(referent) 1(referent) 1(referent)
Bilobar 2.41(1.47–3.94) <0.001 2.05(1.15–3.65) 0.015 2.87(1.49–5.54) 0.002 2.59(1.23–5.45) 0.012
Size of largest metastases
≤ 5 cm 1(referent) 1(referent)
>5 cm 1.18(0.67–2.07) 0.550 1.37(0.64–2.92) 0.407
Timing of metastasis
Synchronous 1(referent) 1(referent)
Metachronous 0.70(0.41–1.19) 0.191 0.77(0.38–1.56) 0.473
Type of neoadjuvant chemotherapy
Oxaliplatin-based chemotherapy 1(referent) 1(referent)
Irinotecan- based chemotherapy 1.48(0.92–2.39) 0.102 1.27(0.64–2.50) 0.485
Preoperative administration of bevacizumab
No 1(referent) 1(referent) 1(referent)
Yes 1.59(0.99–2.54) 0.052 1.57(0.96–2.56) 0.073 1.12(0.58–2.15) 0.727
Response to neoadjuvant chemotherapy
Respondersa 1(referent) 1(referent) 1(referent)
Progression 3.84(1.91–7.71) <0.001 3.60(1.62–7.99) 0.002 2.14(0.82–5.56) 0.118
No. of segments removed
≤ 3 1(referent) 1(referent)
>3 1.40(0.87–2.24) 0.155 1.23(0.65–2.35) 0.514
Primary tumor in situ at the time of hepatectomy
No 1(referent) 1(referent)
Yesb 1.59(0.89–2.84) 0.117 1.16(0.51–2.66) 0.712
Adjuvant chemotherapy
Yes 1(referent) 1(referent) 1(referent) 1(referent)
No 2.27(1.34–3.84) 0.002 1.47(0.79–2.70) 0.217 3.04(1.54–5.99) 0.001 2.10(0.98–4.48) 0.055
Tumeur MCT4 expression
Weak 1(referent) 1(referent)
Strong 0.70(0.43–1.12) 0.145 1.02(0.53–1.95) 0.946
Stromal MCT4 expression
Weak 1(referent) 1(referent) 1(referent) 1(referent)
Strong 1.79(1.12–2.85) 0.014 1.95(1.19–3.17) 0.007 3.81(1.88–7.72) <0.001 4.38(2.15–8.92) <0.001
Abbreviation: CI, conﬁdence interval; DFS, disease free survival; HR, hazards ratio; OS, overall survival; PRS, post recurrence survival.
a Radiologic complete response or radiologic partial response or stable disease (according to RECIST).
b 15 patients underwent synchronous resection of primary tumor and CRLM and 4 patients were managed with the ‘liver ﬁrst’ approach.
41C. Petrides et al. / International Journal of Surgery Open 5 (2016) 37–43
in breast, ovarian, prostate and head and neck cancer (HNSCC), where
epithelial cancer cells have the ability to upregulate MCT4 expres-
sion in stromal cells at a distance, and high stromal MCT4 expression
is associated with a poor prognosis [25–27].
As proved that MCT4 is a marker of oxidative stress and an
overexpression in CRLM could be used in risk stratiﬁcation and
therapy planning. In addition to conventional chemotherapy, an-
tioxidants or autophagy inhibitors could be considered to the group
of patients with increased MCT4 expression [28,29]. Development
of MCT4 or other MCT transporters inhibitors should also be con-
sidered as an advanced step in cancer therapy.
Our results emphasize the importance of an evolving cancer mi-
croenvironment and suggest that therapy should target both
neoplasmatic and stromal cells. The idea of targeting tumor me-
tabolism for cancer treatment has been extensively considered and
is under investigation. Several trials targeted the results of
Lonidamine and TLN232, which deplete hexokinase and pyruvate
kinase respectively [30]. However, given the multiple down-
stream effects on tumor cell metabolism and the complicacy of these
pathways, targeting any nutrient is challenging.
5. Conclusion
The elevated expression of MCT4 in cancer associated stroma pro-
vides a therapeutic window for disabling these transporters with
small-molecule inhibitors. Additional research is needed to cor-
roborate our results and following that MCT4 inhibitors could be
added to current therapeutic protocols and evaluated in clinical prac-
tice.We believe that MCT4 inhibitors could be used as a newweapon
in the treatment of colorectal cancer and liver metastases.
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